Marksans Pharma share news and announcements
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Formerly Tasc Pharmaceuticals
Last close ₹286.90down ₹7.55 (2.56%)BSE ₹286.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹294.45.
52-week range of traded prices to 23 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹13,001 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 25.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 4.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 12 Aug 2026
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 14,14,61953.0% delivered
Marksans Pharma analyst meets
60 filed, newest first. Page 1 of 2.
Sep 2026
1 Sep · Analysts
Aug 2026
Jun 2026
8 Jun · Analysts
May 2026
Feb 2026
Jan 2026
Nov 2025
Oct 2025
Sep 2025
22 Sep · Analysts
Aug 2025
5 Aug · Analysts
May 2025
9 May · Analysts
Mar 2025
21 Mar · Analysts
Jan 2025
30 Jan · Analysts
Dec 2024
11 Dec · Analysts
Nov 2024
5 Nov · Analysts
Sep 2024
2 Sep · Analysts
Jul 2024
31 Jul · Analysts
May 2024
17 May · Analysts
Jan 2024
25 Jan · Analysts
Nov 2023
1 Nov · Analysts
Aug 2023
28 Aug · Analysts
4 Aug · Analysts
May 2023
19 May · Analysts
Feb 2023
4 Feb · Analysts
Jan 2023
24 Jan · Analysts
Nov 2022
Aug 2022
9 Aug · Analysts
Jun 2022
May 2022
24 May · Analysts
Feb 2022
11 Feb · Analysts
Dec 2021
22 Dec · Analysts
21 Dec · Analysts
Nov 2021
18 Nov · Analysts
16 Nov · Analysts
10 Nov · Analysts
Sep 2021
Aug 2021
Jun 2021